The director of the National Medical Products Administration, Li Li, conducted research on drug standard work at the Pharmacopoeia Commission.

On December 3rd, Li Li, the Secretary of the Party Group and Director of the National Medical Products Administration, as well as the Chairman of the 12th Pharmacopoeia Committee, conducted research and chaired a symposium at the National Pharmacopoeia Committee to discuss and deploy further strengthening of China's drug standard related work. Li Li emphasized that the Pharmacopoeia Committee should accurately grasp the requirements of the "13th Five-Year Plan" period, plan the drug standard work in the overall development of China's pharmaceutical industry, and promote the high-quality development of drug standard work with a developmental perspective and reform methods. The committee should strengthen the construction of the expert team, continuously improve the performance level of the committee members, and steadily promote the scientific, institutionalized, and standardized work of drug standardization.